吉列替尼治疗FLT3突变急性髓系白血病研究进展

盘婉盈; 李可昕; 黄宇贤

doi:10.13201/j.issn.1004-2806.2020.11.017

吉列替尼治疗FLT3突变急性髓系白血病研究进展

- 南方医科大学珠江医院血液科(广州, 510282)
基金项目:
国家自然科学基金青年科学基金项目(No:81302372)

详细信息

通讯作者: 黄宇贤,E-mail:hyx6610@163.com

中图分类号: R733.71

收稿日期: 2020-05-15

Progression of gilteritinib in the treatment of FLT3 mutant acute myeloid leukemia

More Information

Corresponding author: HUANG Yu-xian, E-mail: hyx6610@163.com

Received Date: 15 May 2020

摘要

- 吉列替尼 /
- FLT3抑制剂 /
- 急性髓系白血病
Abstract: As a second-generation FLT3 inhibitor,gilteritinib was listed by the NCCN guidelines as the third FLT3 targeted drug for the treatment of relapsed acute myeloid leukemia（AML） in 2019.It is of great significance to understand and study the safety,tolerability,anti-leukemia activity and pharmacokinetics of gilteritinib in the treatment of AML with FLT3 mutations.It will be beneficial for the promotion and popularization of new targeted drugs,and thus enriching the treatment regimen of FLT3^mut+ AML and increasing clinical benefit.This review focuses on the progress of gilteritinib in the treatment of FLT3^mut+ AML.
- gilteritinib /
- FLT3 inhibition /
- acute myeloid leukemia

HTML全文

参考文献(30)

[1]	Tiong IS,Wei AH.New drugs creating new challenges in acute myeloid leukemia[J].Genes Chromosomes Cancer,2019,58:903-914.
[2]	Levis M,Perl AE.Gilteritinib:potent targeting of FLT3 mutations in AML[J].Blood Adv,2020,4:1178-1191.
[3]	Smith CC.The growing landscape of FLT3 inhibition in AML[J].Hematology Am Soc Hematol Edu Program,2019,2019:539-547.
[4]	Gilteritinib Likely New Standard Care for AML[J].Cancer Discov,2019,9:6.
[5]	Sung PJ,Sugita M,Koblish H,et al.Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia[J].Blood Adv,2019,3:1061-1072.
[6]	Crescenzi B,Nofrini V,Barba G,et al.NUP98/11p15 translocations affect CD34+cells in myeloid and T lymphoid leukemias[J].Leuk Res,2015,39:769-772.
[7]	Mori M,Kaneko N,Ueno Y,et al.Gilteritinib,a FLT3/AXL inhibitor,shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia[J].Invest New Drugs,2017,35:556-565.
[8]	Reed DR,Sen JM,Pierce EJ,et al.Gilteritinib:An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients[J].J Oncol Pharm Pract,2020,26:1200-1212.
[9]	Perl AE,Altman JK,Cortes J,et al.Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia:a multicentre,first-in-human,open-label,phase 1-2 study[J].Lancet Oncol,2017,18:1061-1075.
[10]	Sidaway P.Gilteritinib improves outcomes in AML[J].Nat Rev Clin Oncol,2020,17:69.
[11]	Bohl SR,Bullinger L,Rücker FG.New Targeted Agents in Acute Myeloid Leukemia:New Hope on the Rise[J].Int J Mol Sci,2019,20:1983.
[12]	Lee LY,Hernandez D,Rajkhowa T,et al.Preclinical studies of gilteritinib,a next-generation FLT3 inhibitor[J].Blood,2017,129:257-260.
[13]	Cucchi DGJ,Denys B,Kaspers GJL,et al.RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML[J].Blood,2018,131:2485-2489.
[14]	Gorcea CM,Burthem J,Tholouli E.ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation:background and design of the ADMIRAL trial[J].Future Oncol,2018,14:1995-2004.
[15]	Chew S,Mackey MC,Jabbour E.Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation[J].Ther Adv Hematol,2020,11:2040620720930614.
[16]	Usuki K,Sakura T,Kobayashi Y,et al.Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia:An open-label phase 1 study[J].Cancer Sci,2018,109:3235-3244.
[17]	James AJ,Smith CC,Litzow M,et al.Pharmacokinetic Profile of Gilteritinib:A Novel FLT-3 Tyrosine Kinase Inhibitor[J].Clin Pharmacokinet,2020 Apr 18.doi:10.1007/s40262-020-00888-w. Online ahead of print.
[18]	Tarver TC,Hill JE,Rahmat L,et al.Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations[J].Blood Adv,2020,4:514-524.
[19]	Yang F,Anekpuritanang T,Press RD.Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia[J].Mol Diagn Ther,2020,24:1-13.
[20]	Wang ES.Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia[J].Best Pract Res Clin Haematol,2019,32:154-162.
[21]	Ando T,Sano H,Yokoo M,et al.Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor[J].Int J Hematol,2020,112:249-253.
[22]	Tzogani K,Roshol H,Olsen HH,et al.The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation[J].Oncologist,2020,25:e1070-e1076.
[23]	Hogan FL,Williams V,Knapper S.FLT3 Inhibition in Acute Myeloid Leukaemia-Current Knowledge and Future Prospects[J].Curr Cancer Drug Targets,2020,20:513-531.
[24]	Perl AE,Martinelli G,Cortes JE,et al.Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia:Result from the phase III ADMIRAL trial[C].2019 AACR Annual Meeting.Abstract CT184.Presented April 2,2019.
[25]	Elshoury A,Przespolewski A,Baron J,et al.Advancing treatment of acute myeloid leukemia:the future of FLT3 inhibitors[J].Expert Rev Anticancer Ther,2019,19:273-286.
[26]	金洁.急性髓细胞白血病的新药治疗[J].临床血液学杂志,2019,32(3):174-176.
[27]	Wu M,Li C,Zhu X.FLT3 inhibitors in acute myeloid leukemia[J].J Hematol Oncol,2018,11:133.
[28]	Short NJ,Kantarjian H,Ravandi F,et al.Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia[J].Ther Adv Hematol,2019,10:2040620719827310.
[29]	Perl AE,Martinelli G,Cortes JE,et al.FLT3 Gilteritinib or Chemotherapy for Relapsed or Refractory-Mutated AML[J].N Engl J Med,2019,381:1728-1740.
[30]	McMahon CM,Perl AE.Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia[J].Expert Rev Clin Pharmacol,2019,12:841-849.